Last reviewed · How we verify
NCT05742087: Neuro-GFAP
Neuropathy and Anti-GFAP Antibodies
trial testing Clinical examination in Neurological Diseases or Conditions in 120 participants. Status unknown.
1 October 2022
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 September 2022 |
| Primary completion | 1 October 2022 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Clinical examination
- electroneuromyography (ENMG)
Conditions studied
- Neurological Diseases or Conditions — all drugs for Neurological Diseases or Conditions →
- Neurological Diseases Associated to Anti GFAP Antibodies — all drugs for Neurological Diseases Associated to Anti GFAP Antibodies →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Neurological Diseases or Conditions or Neurological Diseases Associated to Anti GFAP Antibodies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From Acute Injury to Chronic Neurodegeneration: Molecular Mechanisms Linking Secondary Brain Injury to Long-Term Pathology.
Kaniuk JK, Kumar D, Mazurek C, Khavari S, et al · · 2025 · cited 1× · PMID 40806328 · DOI 10.3390/ijms26157191
Verify or expand the search:
- PubMed search for NCT05742087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Clinical examination
Trials testing the same drug.
- NCT07353060 — Prognostic Profile of Dupuytren's Disease: a Cohort Study (PRODUCT) · NA · not yet recruiting
- NCT06031714 — Fetal Cell Receptors Repertoire · NA · recruiting
- NCT05492604 — Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP. · NA · completed
- NCT05623449 — Teleconsultations Hypnosis Sessions for Patients with Peripheral Chronic Neuropathic Pain · NA · completed
- NCT06653660 — Exposure to Organochlorine Pollutants and Impact on Development in the Peripubertal Age in Guadeloupe · recruiting
Other recruiting trials for Neurological Diseases or Conditions
Currently open trials in the same condition.
- NCT07254663 — GEL & MEDication Dysphagia · recruiting
- NCT06504433 — The Natural History of Mitochondrial Diseases · recruiting
- NCT04806620 — Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research · recruiting
- NCT05645003 — Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients · NA · recruiting
- NCT04706481 — Archival of Human Biological Samples in CU-Med Biobank · recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05742087 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 23 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing